Equillium (EQ) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Polaryx Therapeutics is the larger company by market cap ($99.2 million vs $90.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | PLYX |
|---|---|---|
| Share price | $1.42 | $1.99 |
| Market cap | $90.04M | $99.19M |
| 1-day change | -1.39% | -0.50% |
| YTD return | -7.10% | — |
| 1-year return | -2.04% | — |
| 5-year return | -75.63% | — |
| EPS (TTM) | $-0.14 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $48.91 |
| 52-week low | $0.76 | $1.85 |
| Distance from 52-week high | -59.89% | -95.93% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +502.82% | +276.88% |
| Average volume | 583.72K | 76.41K |
| Shares outstanding | 63.41M | 49.85M |
| Employees | 14 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
EQ vs PLYX FAQ
Which is bigger, Equillium or Polaryx Therapeutics?
Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $99.19M compared with $90.04M for Equillium (EQ).
Are Equillium and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.